Year All20232022202120202019201820172016201520142013201220112009 Nov 29, 2023 REGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE® Trial Nov 08, 2023 REGENXBIO Announces Updated Strategic Plans and Third Quarter 2023 Financial Results Nov 07, 2023 REGENXBIO to Participate in Upcoming Investor Conferences Nov 03, 2023 REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery Nov 01, 2023 REGENXBIO to Host Conference Call on November 8 to Discuss Third Quarter 2023 Financial Results and Recent Operational Highlights Oct 30, 2023 REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting Oct 05, 2023 REGENXBIO to Participate in the Jefferies CNS/Neuro Summit
Nov 03, 2023 REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
Nov 01, 2023 REGENXBIO to Host Conference Call on November 8 to Discuss Third Quarter 2023 Financial Results and Recent Operational Highlights
Oct 30, 2023 REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting
